The Future of Drug Discovery: Is Generative AI the Next Breakthrough?

New drugs have revolutionized healthcare, with over 200 novel therapeutics gaining FDA approval over the past five years. One key aspect to product success has been – and will continue to be – finding the right drug to bring into development, as up to 85% of new synthetic chemical compounds fail to reach the market. Traditionally, drug candidates have been vetted using a process called high-throughput screening (HTS), where thousands of drug candidates are evaluated through their reactivity with specific biological targets. The hit rate of HTS, however, can be quite low, with some estimates at significantly less than 0.01 percent.

Generative AI promises to transform drug discovery through new approaches to identifying drug candidates. By leveraging recent innovations in AI, companies have mined databases to discover new drug-target interactions or design novel compounds. These revolutionary advances are accelerating the development of treatments for cancers and other complex diseases, improving patient outcomes and reducing healthcare costs. For both startups and established companies, this represents an unprecedented opportunity to reshape the future of drug development.

Featuring pharmaceutical executives, biotech entrepreneurs, and AI innovators, our event panel will explore whether AI is truly a breakthrough in drug discovery, and how it can address long-standing challenges in the industry.

• What are the key approaches to using Generative AI to invent new drug candidates?
• What challenges and limitations remain in AI-driven drug discovery?
• How can startups navigate FDA evaluation of AI-driven drug discovery approaches?
• How are pharmaceutical companies and startups collaborating to accelerate AI-driven innovation around drug discoveries?

Join us on March 20 to peer into the future of drug discovery.

Moderator

• Aaron Arvey, Ph.D., Head of Computational Discovery, Third Rock Ventures

Panelists

• Petrina Kamya, Ph.D., Vice President & Global Head of AI Platforms, Insilico Medicine
• Venkatesh Mysore, Ph.D., Chief Technology Officer and Co-Founder, Aikium
• David Solow-Cordero, Ph.D., Associate Director, High Throughput Screening Knowledge Center & Innovative Medicine Accelerator (IMA), Stanford University
• Lu Wang, Ph.D., Investment Director, Foothill Ventures

==================

Early-Bird Pricing: Limited Availability

The early-bird tickets for this event are 50% off the standard price – but hurry. Only a few seats are available at this special price.

==================

Ticket Includes Food and Drink

==================